The Food and Drug Administration of the United States (FDA) announced this week to recommend only Vaccines Updated COVID-19 for adults aged 65 and over and people at high risk of serious illness against infection.
The FDA now questions the advantages of repeated repair, especially among the otherwise in good health at low risk, which may have already received several doses of COVVI-19 vaccines, had several COVVI-19 infections, or both.
The FDA calls for more trials on the effectiveness of vaccines
The FDA wants these new data to be able to assess how the cocovated shots in this population are currently affecting symptomatic infection and hospitalization and death rates.
“We just don’t know if a 52 -year -old healthy woman with a normal BMI [body mass index] Who had COVVI-19 three times and received six previous doses of a COVVI-19 vaccine will benefit from the seventh dose, “wrote FDA commissioner, Martin Makary, MD, and Vinay Prasad, MD, director of the FDA Biology and Research Center The New England Journal of Medicine editorial. “This policy will require the generation of essential evidence.”
The FDA quotes the hesitation of the vaccine as a reason to limit the vaccination covid
DRS. Makary and Prasad added that the restriction of fire to older Americans and more vulnerable people would align with vaccination policies established by several European nations.
They have written that they expect the benefits of vaccination to continue for adults 65 and over and for every 6 months and more with one or more health problems that put them at high risk of severe covid-19.
The editorial has also stressed that the absorption of Booster coche in the past two seasons has been low, with less than a quarter of Americans receiving photos each year – ranging from less than 10% of children under 12 during the 2024-2025 season to 50% of adults over 75 years of age.
Makary and Prasad argue that the vaccination cocovide can have a “training effect”, resulting in a decrease in public confidence concerning vaccination in general which affects vital immunization programs such as the shooting of measles-rubble (MMR).
Who will be eligible for the cocvid vaccine?
He is uncertain at this stage if a person under 65 or without high -risk health problems will be able to obtain the cocoded vaccine.
But the estimates suggest that 100 to 200 million Americans will still have access to plans with new policy, according to the editorial.
In a live flow on the change of policy, Prasad said that the definition of what makes someone at high risk is an “extremely wide category”.
In addition to age, the editorial listed the following conditions as increasing the risk of severe COVVI-19 infection, as defined by the CDC:
Robert H. Hopkins Jr., MD, medical director of the National Foundation for Infectious Diseases, affirms that the description by the FDA of which will have access to vaccination must be more clarified.
“The editorial implies that the list of conditions that put people at increased risks of COVID-19 serious could be reassessed, but that is not clearly stated,” said Dr. Hopkins.
The advantages of the planned changes
Hopkins sees both strengths and weaknesses in the proposed plan.
On the one hand, he considers that it is encouraging that the process of assessing and approving new versions of COVVI-19 vaccines continues, which is in accordance with long-standing regulatory practices in the United States and other countries. In addition, continuous access to COVVI-19 vaccines is ensured for adults 65 and over, as well as for people at risk of serious illness.
He notes that new clinical trials could provide more robust evidence of the impact of vaccination between different age groups and other subpopulations.
Why the plan can be risky
Hopkins stresses that questions remain on who will support the cost of new clinical trials.
“If the financial burden falls too much to manufacturers, this could reduce their desire to continue to produce updated vaccines, possibly increase costs and limit availability,” he says.
The greatest weakness of the plan, however, is likely to limit access and coverage of vaccines, says Hopkins. He thinks that a large vaccination is the key to reducing community transmission and protecting public health.
“From the early stages of the pandemic, we have had trouble reaching high vaccination coverage through the general population,” explains Hopkins. “Consequently, COVID-19 continued to circulate in our communities. The risk remains that a new, more transmissible or severe variant can emerge. If this happens, access to limited vaccination could leave us vulnerable – not only medically, but also in terms of pressure on our health system and the broader social and economic impact. ”
The possibility that COVID-19 returns to the pandemic levels remains.
“The limitation of generalized access to vaccination increases the risk of future epidemics and weakens our ability to respond quickly if the virus evolves,” explains Hopkins. “We must remain vigilant and flexible in our policies to ensure that we are prepared for what comes next.”
:max_bytes(150000):strip_icc()/VWH-GettyImages-1296737069-d60f07eb91ca42968f569f4a1bf0c74f.jpg?w=390&resize=390,220&ssl=1 "Est-il sûr de se gargariser avec du peroxyde d’hydrogène?")
